Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

Objectives: The aim of this study was to review the requirements for the reimbursement of biosimilars and to compare the reimbursement status, market share, and reimbursement costs of biosimilars in selected Central and Eastern European (CEE) countries.Methods: A questionnaire-based survey was condu...

Full description

Bibliographic Details
Main Authors:	Paweł Kawalec, Ewa Stawowczyk, Tomas Tesar, Jana Skoupa, Adina Turcu-Stiolica, Maria Dimitrova, Guenka I. Petrova, Zinta Rugaja, Agnes Männik, Andras Harsanyi, Pero Draganic
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-06-01
Series:	Frontiers in Pharmacology
Subjects:	biosimilar pharmaceuticals pricing reimbursement original products interchangeability
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2017.00288/full

Similar Items

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
by: Paweł Kawalec, et al.
Published: (2017-12-01)

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
by: Olga Barszczewska, et al.
Published: (2020-06-01)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
by: Evelien Moorkens, et al.
Published: (2020-01-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-01-01)

Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
by: Krzysztof Piotr Malinowski, et al.
Published: (2020-10-01)

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift
by: Eva Rahman Kabir, et al.
Published: (2018-09-01)

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
by: Vesa Halimi, et al.
Published: (2020-08-01)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
by: Krzysztof Piotr Malinowski, et al.
Published: (2019-05-01)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01)

Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists
by: Shakeel S, et al.
Published: (2020-11-01)

The biosimilars journey: current status and ongoing challenges
by: Igor Age Kos, et al.
Published: (2018-10-01)

Focus on biosimilar etanercept – bioequivalence and interchangeability
by: Cantini F, et al.
Published: (2018-08-01)

Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far
by: Anna La Noce, et al.
Published: (2018-09-01)

Potential Cost-Savings From the Use of the Biosimilars in Slovakia
by: Tomas Tesar, et al.
Published: (2020-08-01)

Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country
by: Edward Mezones-Holguin, et al.
Published: (2019-11-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
by: Becciolini A, et al.
Published: (2017-06-01)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
by: Olga Barszczewska, et al.
Published: (2021-06-01)

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary
by: Arnon D. Cohen, MD, MPH, PhD, et al.
Published: (2020-12-01)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
by: Maria Kamusheva, et al.
Published: (2018-07-01)

Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge
by: Filipe C. Araújo, et al.
Published: (2018-07-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-06-01)

The safety of biological preparations. Part 2. Safety issues of biosimilars
by: A. A. Soldatov, et al.
Published: (2018-02-01)

Biosimilars in rheumatology and other fields of medicine
by: Marcin Milchert, et al.
Published: (2014-07-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2021-12-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Biosimilars in oncology: characteristics and insights
by: Stefano Cascinu
Published: (2013-06-01)

Biosimilars in Europe
Published: (2023)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_mbtft7g5hbtc8m47899hi2lap1